Hanieh Abedian Kalkhoran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hanieh Abedian Kalkhoran has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Egbert F. Smit
3 shared publicationsHenk Codrington
3 shared publications- Juliette Zwaveling
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications Juliëtte Zwaveling
3 shared publicationsLoes E. Visser
3 shared publicationsDanielle Cohen
Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands
2 shared publications
Latest Publications
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2500383
Validation of a Text-Mining Tool for Extracting Routine Clinical Care Data in Early-Stage Resectable Non–Small Cell Lung Cancer
PURPOSE: Manual chart review (MR) of electronic health records (EHRs) is time-consuming, error-prone, and limits the reproducibility and scalability of real-world data (RWD) research. Automation and standardization using natural language processing (NLP) could improve efficiency and scalability. CTcue is an NLP-based software platform designed to extract structured and unstructured data from EHRs. This study evaluated the accuracy and efficiency of CTcue versus MR in patients with early-stage resectable non–small cell lung cancer (NSCLC). METHODS: Included were all patients with stage I to III NSCLC who underwent lung resections between January 2018 and December 2021 at the Leiden University Medical Center, the Netherlands. Demographics, tumor characteristics, treatment, and outcomes were collected. CTcue performance was compared with MR using weighted F1-scores, accuracy, precision, and recall for categorical variables and Bland-Altman analysis for continuous variables. RESULTS: Eighty-five patients (70.2% of patients from the manual cohort) were identified by both methods and included in the comparison. CTcue achieved weighted F1-scores >0.85 for seven of 15 categorical variables, including sex, tumor location, and deceased status, although some scores were based on low number of observations in both cohorts. Lower performance was observed for variables with varying terminology in documentation, such as Eastern Cooperative Oncology Group status and pathological N-stage. Continuous variables showed negligible mean differences, indicating good agreement. Survival outcomes were identical in both data sets. CONCLUSION: CTcue performance for patient selection was lower than anticipated. However, it enables accurate, efficient extraction of structured and unstructured EHR data in early-stage NSCLC. Manual validation remains necessary for variables with varying terminology. Further development of artificial intelligence-based tools—particularly for free-text data extraction—will be crucial to enhance the accuracy and scalability of future RWD research.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3) , e2500383
Validation of a Text-Mining Tool for Extracting Routine Clinical Care Data in Early-Stage Resectable Non–Small Cell Lung Cancer
PURPOSE: Manual chart review (MR) of electronic health records (EHRs) is time-consuming, error-prone, and limits the reproducibility and scalability of real-world data (RWD) research. Automation and standardization using natural language processing (NLP) could improve efficiency and scalability. CTcue is an NLP-based software platform designed to extract structured and unstructured data from EHRs. This study evaluated the accuracy and efficiency of CTcue versus MR in patients with early-stage resectable non–small cell lung cancer (NSCLC). METHODS: Included were all patients with stage I to III NSCLC who underwent lung resections between January 2018 and December 2021 at the Leiden University Medical Center, the Netherlands. Demographics, tumor characteristics, treatment, and outcomes were collected. CTcue performance was compared with MR using weighted F1-scores, accuracy, precision, and recall for categorical variables and Bland-Altman analysis for continuous variables. RESULTS: Eighty-five patients (70.2% of patients from the manual cohort) were identified by both methods and included in the comparison. CTcue achieved weighted F1-scores >0.85 for seven of 15 categorical variables, including sex, tumor location, and deceased status, although some scores were based on low number of observations in both cohorts. Lower performance was observed for variables with varying terminology in documentation, such as Eastern Cooperative Oncology Group status and pathological N-stage. Continuous variables showed negligible mean differences, indicating good agreement. Survival outcomes were identical in both data sets. CONCLUSION: CTcue performance for patient selection was lower than anticipated. However, it enables accurate, efficient extraction of structured and unstructured EHR data in early-stage NSCLC. Manual validation remains necessary for variables with varying terminology. Further development of artificial intelligence-based tools—particularly for free-text data extraction—will be crucial to enhance the accuracy and scalability of future RWD research.
- Open Access
- 10 June 2026
- Published by Elsevier in International Journal of Lung Cancer
- Vol. 1 (3)
First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility
- 10 June 2026
- Published by Elsevier in International Journal of Lung Cancer
- Vol. 1 (3)
Open AccessFirst-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility
- Open Access
- 17 July 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (7) , e599-e608.e2
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
- 17 July 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (7) , e599-e608.e2
Open AccessReal World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
- Open Access
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400053
Development and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non–Small Cell Lung Cancer
PURPOSE: The objective was to develop and evaluate the portability of a text mining algorithm for prospectively capturing disease progression in electronic health record (EHR) data of patients with metastatic non–small cell lung cancer (mNSCLC) treated with immunochemotherapy. METHODS: This study used EHR data from patients with mNSCLC receiving immunochemotherapy (between October 1, 2018, and December 31, 2022) in four Dutch hospitals. A text mining algorithm for capturing disease progression was developed in hospitals 1 and 2 and then transferred to hospitals 3 and 4 to evaluate portability. Performance metrics were calculated by comparing its outcomes with manual chart review. In addition, data were simulated to come available over time to assess performance in real-time applications. Median progression-free survival (PFS) was calculated using the Kaplan-Meier method to compare text mining with manual chart review. RESULTS: During development and portability, the text mining algorithm performed well in capturing disease progression, with all performance scores >90%. When real-time performance was simulated, the performance scores in all four hospitals exceeded 90% from week 15 after the start of follow-up. Although the exact progression dates varied in 46 patients of 157 patients with progressive disease, the number of patients labeled with progression too early (n = 24) and too late (n = 22) was well balanced with discrepancies ranging from –116 to 384 days. Nevertheless, the PFS curves constructed with text mining and manual chart review were highly similar for each hospital. CONCLUSION: In this study, an accurate text mining algorithm for capturing disease progression in the EHR data of patients with mNSCLC was developed. The algorithm was portable across different hospitals, and the performance over time was good, making this an interesting approach for prospective follow-up of multicenter cohorts.
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400053
Open AccessDevelopment and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non–Small Cell Lung Cancer
PURPOSE: The objective was to develop and evaluate the portability of a text mining algorithm for prospectively capturing disease progression in electronic health record (EHR) data of patients with metastatic non–small cell lung cancer (mNSCLC) treated with immunochemotherapy. METHODS: This study used EHR data from patients with mNSCLC receiving immunochemotherapy (between October 1, 2018, and December 31, 2022) in four Dutch hospitals. A text mining algorithm for capturing disease progression was developed in hospitals 1 and 2 and then transferred to hospitals 3 and 4 to evaluate portability. Performance metrics were calculated by comparing its outcomes with manual chart review. In addition, data were simulated to come available over time to assess performance in real-time applications. Median progression-free survival (PFS) was calculated using the Kaplan-Meier method to compare text mining with manual chart review. RESULTS: During development and portability, the text mining algorithm performed well in capturing disease progression, with all performance scores >90%. When real-time performance was simulated, the performance scores in all four hospitals exceeded 90% from week 15 after the start of follow-up. Although the exact progression dates varied in 46 patients of 157 patients with progressive disease, the number of patients labeled with progression too early (n = 24) and too late (n = 22) was well balanced with discrepancies ranging from –116 to 384 days. Nevertheless, the PFS curves constructed with text mining and manual chart review were highly similar for each hospital. CONCLUSION: In this study, an accurate text mining algorithm for capturing disease progression in the EHR data of patients with mNSCLC was developed. The algorithm was portable across different hospitals, and the performance over time was good, making this an interesting approach for prospective follow-up of multicenter cohorts.
- Open Access
- 16 May 2024
- Published by Springer Nature in Journal of Medical Systems
- Vol. 48 (1) , 1-8
An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records
Reports from spontaneous reporting systems (SRS) are hypothesis generating. Additional evidence such as more reports is required to determine whether the generated drug-event associations are in fact safety signals. However, underreporting of adverse drug reactions (ADRs) delays signal detection. Through the use of natural language processing, different sources of real-world data can be used to proactively collect additional evidence for potential safety signals. This study aims to explore the feasibility of using Electronic Health Records (EHRs) to identify additional cases based on initial indications from spontaneous ADR reports, with the goal of strengthening the evidence base for potential safety signals. For two confirmed and two potential signals generated by the SRS of the Netherlands Pharmacovigilance Centre Lareb, targeted searches in the EHR of the Leiden University Medical Centre were performed using a text-mining based tool, CTcue. The search for additional cases was done by constructing and running queries in the structured and free-text fields of the EHRs. We identified at least five additional cases for the confirmed signals and one additional case for each potential safety signal. The majority of the identified cases for the confirmed signals were documented in the EHRs before signal detection by the Dutch Medicines Evaluation Board. The identified cases for the potential signals were reported to Lareb as further evidence for signal detection. Our findings highlight the feasibility of performing targeted searches in the EHR based on an underlying hypothesis to provide further evidence for signal generation.
- 16 May 2024
- Published by Springer Nature in Journal of Medical Systems
- Vol. 48 (1) , 1-8
Open AccessAn innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records
Reports from spontaneous reporting systems (SRS) are hypothesis generating. Additional evidence such as more reports is required to determine whether the generated drug-event associations are in fact safety signals. However, underreporting of adverse drug reactions (ADRs) delays signal detection. Through the use of natural language processing, different sources of real-world data can be used to proactively collect additional evidence for potential safety signals. This study aims to explore the feasibility of using Electronic Health Records (EHRs) to identify additional cases based on initial indications from spontaneous ADR reports, with the goal of strengthening the evidence base for potential safety signals. For two confirmed and two potential signals generated by the SRS of the Netherlands Pharmacovigilance Centre Lareb, targeted searches in the EHR of the Leiden University Medical Centre were performed using a text-mining based tool, CTcue. The search for additional cases was done by constructing and running queries in the structured and free-text fields of the EHRs. We identified at least five additional cases for the confirmed signals and one additional case for each potential safety signal. The majority of the identified cases for the confirmed signals were documented in the EHRs before signal detection by the Dutch Medicines Evaluation Board. The identified cases for the potential signals were reported to Lareb as further evidence for signal detection. Our findings highlight the feasibility of performing targeted searches in the EHR based on an underlying hypothesis to provide further evidence for signal generation.
- Open Access
- 14 March 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-12
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
Background: This study was designed to investigate the impact of age on the effectiveness and immune-related adverse events (irAEs) of programmed death-(ligand)1 [PD-(L)1] inhibitors in patients with non-small cell lung cancer (NSCLC) using a novel text-mining technique. Methods: This retrospective study included patients with stage III/IV NSCLC treated with a PD-(L)1 inhibitor (nivolumab, pembrolizumab, atezolizumab and durvalumab) at Leiden University Medical Centre and Haga Teaching hospital, (both in The Netherlands) from September 2016 to May 2021. All the relevant data was extracted from the structured and unstructured fields of the Electronic Health Records using a novel text-mining tool. Effectiveness [progression-free survival (PFS) and overall survival (OS)] and safety (the incidence of nine potentially fatal irAEs and systemic corticosteroid requirement) outcomes were compared across age subgroups (young: < 65 years, Middle-aged: 65–74 years, and old: ≥ 75 years) after adjustment for confounding. Results: Of 689 patients, 310 patients (45.0%) were < 65 years, 275 patients (39.9%) were aged between 65 and 74 years, and 104 patients (15.1%) were ≥ 75 years. There was no significant difference between younger and older patients regarding PFS (median PFS 12, 8, 13 months respectively; Hazard ratio (HR)middle-aged = 1.14, 95% CI 0.92–1.41; HRold = 1.10, 95% CI 0.78–1.42). This was also the case for OS (median OS 19, 14, 18 months respectively; HRmiddle-aged = 1.22, 95% CI 0.96–1.53; HRold = 1.10, 95% CI 0.79–1.52). Safety analysis demonstrated a higher incidence of pneumonitis among patients aged 65–74. When all the investigated irAEs were pooled, there was no statistically significant difference found between age and the incidence of potentially fatal irAEs. Conclusions: The use of PD-(L)1 inhibitors is not associated with age related decrease of PFS and OS, nor with increased incidence of serious irAEs compared to younger patients receiving these treatments. Chronological age must therefore not be used as a predictor for the effectiveness or safety of ICIs.
- 14 March 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-12
Open AccessA text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
Background: This study was designed to investigate the impact of age on the effectiveness and immune-related adverse events (irAEs) of programmed death-(ligand)1 [PD-(L)1] inhibitors in patients with non-small cell lung cancer (NSCLC) using a novel text-mining technique. Methods: This retrospective study included patients with stage III/IV NSCLC treated with a PD-(L)1 inhibitor (nivolumab, pembrolizumab, atezolizumab and durvalumab) at Leiden University Medical Centre and Haga Teaching hospital, (both in The Netherlands) from September 2016 to May 2021. All the relevant data was extracted from the structured and unstructured fields of the Electronic Health Records using a novel text-mining tool. Effectiveness [progression-free survival (PFS) and overall survival (OS)] and safety (the incidence of nine potentially fatal irAEs and systemic corticosteroid requirement) outcomes were compared across age subgroups (young: < 65 years, Middle-aged: 65–74 years, and old: ≥ 75 years) after adjustment for confounding. Results: Of 689 patients, 310 patients (45.0%) were < 65 years, 275 patients (39.9%) were aged between 65 and 74 years, and 104 patients (15.1%) were ≥ 75 years. There was no significant difference between younger and older patients regarding PFS (median PFS 12, 8, 13 months respectively; Hazard ratio (HR)middle-aged = 1.14, 95% CI 0.92–1.41; HRold = 1.10, 95% CI 0.78–1.42). This was also the case for OS (median OS 19, 14, 18 months respectively; HRmiddle-aged = 1.22, 95% CI 0.96–1.53; HRold = 1.10, 95% CI 0.79–1.52). Safety analysis demonstrated a higher incidence of pneumonitis among patients aged 65–74. When all the investigated irAEs were pooled, there was no statistically significant difference found between age and the incidence of potentially fatal irAEs. Conclusions: The use of PD-(L)1 inhibitors is not associated with age related decrease of PFS and OS, nor with increased incidence of serious irAEs compared to younger patients receiving these treatments. Chronological age must therefore not be used as a predictor for the effectiveness or safety of ICIs.